21,958 Shares in Kenvue Inc. (NYSE:KVUE) Purchased by Bryce Point Capital LLC

Bryce Point Capital LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 21,958 shares of the company’s stock, valued at approximately $469,000.

Several other hedge funds also recently modified their holdings of KVUE. Huntington National Bank lifted its holdings in Kenvue by 44.4% in the fourth quarter. Huntington National Bank now owns 6,007 shares of the company’s stock valued at $128,000 after buying an additional 1,846 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after acquiring an additional 10,682,003 shares during the last quarter. Headlands Technologies LLC lifted its stake in shares of Kenvue by 231.2% in the 4th quarter. Headlands Technologies LLC now owns 34,317 shares of the company’s stock valued at $733,000 after purchasing an additional 23,957 shares during the period. Boston Family Office LLC bought a new position in shares of Kenvue in the 4th quarter worth $243,000. Finally, Geode Capital Management LLC grew its stake in shares of Kenvue by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock worth $980,989,000 after purchasing an additional 1,391,854 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on KVUE shares. Barclays upped their target price on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday, March 27th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Canaccord Genuity Group boosted their target price on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Finally, Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average price target of $24.00.

Kenvue Stock Down 5.5 %

Shares of KVUE stock opened at $22.33 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market cap of $42.68 billion, a price-to-earnings ratio of 42.14, a PEG ratio of 2.62 and a beta of 1.25. The firm’s 50-day moving average is $22.59 and its 200-day moving average is $22.47.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.